Seres Therapeutics

Seres Therapeutics Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Seres Therapeutics key operating metrics including R&D Expenses (SER-109), environmental, and social and governance score (ESG).

R&D Expenses (SER-109)

$13.3M

24.2%

Q2, 2022

R&D Expenses (SER-287)

$819K

76.4%

Q2, 2022

Facilities Leased, sq. ft.

83.4K

FY, 2021

Operating Metrics

Metrics	FY, 2019	FY, 2020	FY, 2021
R&D Expenses (SER-109)	$10.3M	$14.9M	$40.5M
R&D Expenses (SER-287)	$17.4M	$16.3M	$9.9M
Facilities Leased, sq. ft.	83.4K	83.4K	83.4K
Patent Application Families	24	23	24
Patents (US)	18	14	18
R&D Expenses (Microbiome therapeutics platform)	$52.3M	$54.0M	$34.8M
Early Stage Programs		$5.3M	$5.0M

40-49 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub